How narrow is Trump’s final Medicare drug pricing rule for Part B drugs?

Trump’s Sept. 30 final Medicare drug pricing rule appears far narrower than originally proposed. The summary says it applies to only four companies and delivers savings 96% lower than the initial approach, suggesting limited immediate market impact but preserving the precedent of using a global benchmark in Medicare drug pricing.